Hypothesis

Age-related decline in base excision repair isn't simply a matter of reduced enzyme levels. I've come to think the real problem is a kinetic bottleneck: as 8-oxoG lesions accumulate, they stack up and actually slow down OGG1 turnover—the enzyme gets stuck on existing lesions rather than cycling through efficiently. Then MUTYH tries to repair the adenine mispairs that form opposite these lesions, but this generates single-strand breaks that hyperactivate PARP1. The auto-poly(ADP-ribosyl)ation reaction burns through NAD+, while POLβ's gap-filling step needs ATP—both of which are in short supply in aging neurons. The result is a self-reinforcing loop where each BER cycle takes longer and costs more energy, eventually overwhelming the repair capacity of aged neurons entirely.

Mechanistic Basis

OGG1 shows substrate inhibition at high lesion densities—clustered 8-oxoG damage simply can't be accessed sequentially. This is well documented. What I'm suggesting is that aged neurons, which accumulate 8-oxoG to levels roughly 8-fold above baseline, enter a regime where OGG1 molecules get sequestered on persistent lesions instead of turning over normally. The attempted repair by MUTYH makes things worse by creating additional SSBs, which triggers PARP1 hyperactivation. Since POLβ-mediated gap-filling requires ATP and PARPAR1 auto-PARylation consumes NAD+, neurons already suffering from compromised mitochondrial function face a genuine bioenergetic crisis that further drags down repair kinetics.

Testable Predictions

• In vitro: Oxidant-stressed primary neurons from aged mice should show slower OGG1 turnover (measurable via single-molecule imaging) compared to young neurons, with the deficit rescued by PARP1 inhibition.

• Ex vivo: Brain slices from aged rodents treated with PARG inhibitors (which enhance PAR turnover) ought to clear 8-oxoG faster than vehicle-treated controls.

• In vivo: Crossing OGG1-overexpressing mice with PARP1 haploinsufficient mice should produce synergistic cognitive benefits exceeding what either genetic modification achieves alone.

Falsifiability

The model would fall apart if OGG1 turnover rates in aged neurons turn out to be equivalent to young neurons under the same lesion load, or if PARP1 inhibition doesn't speed up 8-oxoG clearance.

This mechanism explains why MUTYH activity can actually drive neurodegeneration despite being a repair enzyme, and why OGG1 agonists show therapeutic promise—both reducing lesion burden and keeping the repair cycle moving are essential for maintaining genomic integrity in neurons.